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Results: Loss of a5 integrin expression was related to chondrocyte
dedifferentiation in the osteoarthritic articular cartilage, while a1, a2
and a3 integrin expression increased in ﬁbrous areas in osteoarthritic
cartilage. The aV integrin was expressed in hyperthrophic cartilage
and increased in the articular cartilage of osteoarthritic rats, where
bone was developed and neovascularization was observed. The effect of
GDF-5 (growth differentiation factor 5) and BMP-7 (bone morphogenetic
protein 7) on integrins expression during chondrocytes differentiation
was also analyzed. A micromasses culture system of mouse embryo
mesenchymal cells, were treated with GDF-5 or BMP-7 for 4 and 6 days.
The expression of integrins was analyzed by immunohistochemistry.
GDF-5 induced the expression of a5 sub-unit while BMP-7 induced
the expression of aV sub-unit. This suggests a switch in the signal
for chondral differentiation towards hypertrophy, where GDF-5 could
keep the state of the articular chondrocyte and BMP-7 would induce
hypertrophy. The typical chondrocyte phenotype in the articular cartilage
is preserved due to the presence of Indian hedgehog (Ihh), which is
dependent on a5 integrin and GDF-5 to keep the articular cartilage and
prevent hypertrophy. This was supported by decrease of Ihh expression in
articular cartilage during OA. Treating mouse knees organ cultures with
Cyclopamine an Ihh signaling inhibitor, articular cartilage ossiﬁcation
was observed similarly with OA rat knees, probably by a process
apparently similar to endochondral ossiﬁcation.
Conclusions: The typical chondrocyte phenotype in the articular
cartilage is preserved due to the presence of Indian hedgehog (Ihh),
which is dependent on a5 integrin and GDF-5 to keep the articular
cartilage phenotype and prevent hypertrophy and OA.
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ALARMINS S100A8 AND S100A9 ELICIT AN ENHANCED CATABOLIC
RESPONSE IN CHONDROCYTES FROM OSTEOARTHRITIS PATIENTS
THAT IS TOLL LIKE RECEPTOR 4 DEPENDENT
R.F. Schelbergen1, A.B. Blom1, M.H. van den Bosch1, A. Sloetjes1,
W. Schreurs2, T. Vogl3, J. Roth3, W.B. van den Berg1, P.L. van Lent1. 1Dept.
Rheumatology, Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands;
2Dept. Orthopaedics, Radboud Univ. Nijmegen Med. Ctr., Nijmegen,
Netherlands; 3Inst. of Immunology, Univ. of Muenster, Muenster, Germany
Purpose: S100A8 and S100A9 are two Ca2+-binding proteins classiﬁed
as damage associated molecular patterns (DAMPs) or alarmins that
are found in high amounts in the synovial ﬂuid of osteoarthritis (OA)
patients. Previously, we found that S100A8 and S100A9 are associated
with cartilage degradation in murine collagenase-induced OA. We also
showed that S100A8 and S100A9 stimulate expression and activity of
matrix metalloproteinases (MMPs) and pro-inﬂammatory cytokines in
murine chondrocytes. In the current study, we investigated whether and
via which receptor S100A8 and/or S100A9 can have a catabolic effect on
chondrocytes from OA patients.
Methods: Using immunohistochemistry, we stained for S100A8 and
S100A9 protein, MMPs and a cartilage breakdown epitope speciﬁc for
MMPs (VDIPEN) in cartilage from OA donors. Isolated chondrocytes or
explants from OA and non-OA donors were stimulated with S100A8
and/or S100A9. mRNA and protein levels of MMPs, cytokines and
cartilage matrix molecules were determined with RT-qPCR and Luminex.
For receptor blocking studies, speciﬁc inhibitors for Toll-like receptor
4 (TLR4) (intracellular TAK242) and RAGE and carboxylated glycans
(blocking antibodies) were used.
Results: In cartilage of OA patients, localisation of S100A8 and S100A9
protein was found close to chondrocytes and was associated with
proteoglycan (PG) depletion, MMP1 and -3 and VDIPEN expression.
Stimulation of chondrocytes with S100A8 and S100A9 caused a
signiﬁcant upregulation of MMP1, -3, -9 and -13 at the mRNA (4.7-fold
mean increase) and the protein level (3.0-fold mean increase). Moreover,
S100A8 and S100A9 caused a huge increase in cytokine and chemokine
expression. IL-6, IL-8 andMCP-1 were all greatly increased by S100A8 and
S100A9 at both the mRNA (19.7-fold mean increase) as well as the protein
level (28.8-fold mean increase). Thereby, the expression of anabolic
markers (aggrecan and collagen type II) was signiﬁcantly reduced at the
mRNA level (2.7-fold mean decrease). Together, upregulation of MMPs
and cytokines and downregulation of production of cartilage matrix
molecules favor cartilage loss by the OA chondrocyte.
Blocking TLR4 inhibited the upregulation of MMPs, IL-6, IL-8, MCP-1
and collagen type II by S100A9 in OA chondrocytes. In contrast, the
blocking of carboxylated glycans and RAGE did not alter the S100-effects.
Finally, the catabolic effect of S100A8 and S100A9 was signiﬁcantly more
pronounced in chondrocytes from OA patients when compared to non-
OA. TLR4 mRNA expression was enhanced in OA chondrocytes, which
might be the underlying mechanism of increased sensitivity.
Conclusions: S100A8 and S100A9 have a catabolic effect on human
chondrocytes that is dependent on TLR4. OA chondrocytes are more
sensitive for S100-stimulation than normal chondrocytes.
This study underlines the potential of S100A8 and S100A9 as mediators
of cartilage damage during OA.
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F-SPONDIN MEDIATES CATABOLIC EFFECTS ON ARTICULAR
CHONDROCYTES VIA ITS THROMBOSPONDIN REPEAT (TSR) DOMAIN
J. Liu, G. Palmer, Q. Yang, D. Rifkin, M. Attur, S.B. Abramson. NYUHosp.
for Joint Diseases, New York, NY, USA
Purpose: We have previously shown that the thrombospondin-related,
extracellular matrix protein, F-spondin, is upregulated in osteoarthritis
(OA), and induces the production of catabolic mediators, PGE2 and MMP-
13 in cartilage explants in a TGF-b dependent manner. In this study,
we characterize the role of individual protein domains of F-spondin in
modulating its catabolic effects in chondrocytes.
Methods: OA chondrocytes were harvested from tibial cartilage obtained
from OA patients with end-stage disease undergoing knee replacement
surgery. Transient transfections were performed using TransIT-LT1
reagent (Mirus) and cDNAs encoding full length (FS1) or a truncated
C-terminal (FS7) portion of F-spondin coding sequence. Levels of TGF-b1
(R&D systems) and PGE2 (Cayman Chemical) were determined by ELISA,
MMP-13 expression was measured by qRT-PCR (Applied Biosystems).
TGF-b activity was also measured in conditioned media supernatants
by incubation with mink lung epithelial cells (MLEC) expressing a TGF-
b-responsive luciferase reporter.
Results: Consistent with our previous observations of the effects
of intact F-spondin in cartilage explants, overexpression of FS1 in
cultured OA chondrocytes from 3 patients increased expression levels
of MMP-13 ~100% compared to mock-transfected controls. Similarly,
FS1 also increased PGE2 levels by 25% (p < 0.05). Both effects could be
mimicked by transfection with a construct encoding only the c-terminal
TSR repeat domain FS7; MMP-13 and PGE2 levels were elevated by
FS7 above control vector transfected cultures, ~50% (p < 0.005) and
71% (p < 0.05), respectively. Since the F-spondin TSR domain harbors
consensus sequences for latent TGF-b activation (WxxW and KRFK),
we tested whether F-spondin overexpression increases TGF-b levels
and activity in chondrocyte cultures. In OA chondrocytes, TGF-b levels
in culture supernatants were increased 30% by FS1 and 70% by FS7.
Similarly, measurement of active TGF-b using MLEC reporter cells showed
that FS1 and FS7-transfected culture media supernatants stimulated
luciferase activity 30% and 100%, respectively (p < 0.05). Evidence of
enhanced activation of TGF-b was also demonstrated by increased SMAD
signaling. Immunoblot of FS treated chondrocytes showed increased
phosphorylation of SMAD 1, 5, 8 relative to mock transfected cells.
Similarly, both FS1 and FS7 stimulated expression of a SMAD-luciferase
reporter in OA chondrocytes.
Conclusions: Our data provide evidence that F-spondin, via its TSR
domain, can act as a latent TGF-b-activating protein and enhance the
catabolic activity of chondrocytes via induction of MMP-13 and PGE2. The
TSR domain of F-spondin may therefore represent a novel therapeutic
target for slowing cartilage breakdown in OA.
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INHIBITING CALCINEURIN ACTIVITY UNDER PHYSIOLOGICAL
CONDITIONS SELECTIVELY PREVENTS ARTICULAR CHONDROCYTE
HYPERTROPHY
A.E. van der Windt, E. Haak, J.A. Verhaar, H. Weinans, H. Jahr. Erasmus
MC, Rotterdam, Netherlands
Purpose: Proliferation and hypertrophic differentiation of chondrocytes
as well as extracellular matrix (ECM) mineralization and chondrocytes
apoptosis occur during the course of osteoarthritis (OA). OA is
further characterized by an imbalanced production of ECM-degrading
enzymes such as matrix metalloproteinases (MMPs) and aggreganases
(ADAMTS’), which deplete major structural components like collagens
(COLs) and proteoglycans (PGs, e.g. aggrecan) from the ECM. Both
chondrogenic markers are crucial to biomechanical strength and
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hydrostatic pressurization of cartilage. The tissue’s ﬁxed negative charge
density is determined by the glycosaminoglycan (GAG) chains in the PGs.
Healthy cartilage has a (physiological) tonicity of 350–480 mOsm, while
the tonicity of the ECM in OA stage-dependently approaches plasma
values (i.e. ~280mOsm). Culturing chondrocytes under tonic conditions
improves their phenotype. Calcineurin inhibition promotes chondrogenic
marker expression and is known to regulate cellular hypertrophy in other
tissues.
We aimed to elucidate if modulating calcineurin activity under
physiological conditions can improve the chondrogenic phenotype while
preventing hypertrophic differentiation of human chondrocytes in vitro.
Methods: Human articular chondrocytes (HACs) were isolated and
cultured in DMEM of 380 and 280mOsm (control) with or without
addition of calcineurin inhibitor FK506 in passage 1 (P1) and
P2. Chondrogenic (COL types -II, -IX, -XI; aggrecan, matrilin 1),
(pre-)hypertrophic (Ihh, COL-X, MMP-13; alkaline phosphatase, ALP;
VEGF), catabolic (MMPs, ADAMTS’) and osteogenic (COL-I, Runx2, SPP-1)
markers were evaluated on mRNA and protein level in 2D monolayer
cultures and 3D microtissues. Treatment was also evaluated employing
non-arthritic chondrocytes and cartilage explants as was the contribution
of TGFb/BMP signaling.
Results: Compared to the 280mOsm control, culturing HACs at
physiological tonicity (380mOsm) showed a general beneﬁcial trend
in chondrogenic marker expression, with increased mRNA levels of
COL2, AGC and SOX9 and suppression of unwanted COL1. Inhibiting
calcineurin activity using FK506 further improved the anabolic effects of
physiological tonicity (e.g. COL2 50-fold, n = 6; veriﬁed on protein level in
2D and 3D), but decreased tonicity-induced expression of collagenases
and aggrecanases. The tonicity-induced expression of hypertrophy
markers COL-X, MMP-13 and ALPL was selectively, dose-dependently
inhibited by FK506 (n =6), which also reduced ALPL and MMP13 activity.
Similar effects were found in non-arthritic chondrocytes and cartilage
explants (n = 3 patients ea.). TGFb superfamily members were selectively
up-regulated by tonicity, while FK506 seems to antagonize BMP-induced
hypertrophic differentiation.
Conclusions: Physiological tonicity largely improves chondrogenic
marker expression in primary human chondrocytes in vitro, but
up-regulates several hypertrophic markers. Under these conditions,
inhibition of calcineurin activity selectively suppresses catabolic and
hypertrophic markers, which is at least partially mediated by TGFb
superfamily signaling. Our ﬁnding may open new venues in the
treatment of OA.
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COUNTER-REGULATION OF CHONDROCYTE MATRIX HOMEOSTASIS BY
OPPOSING ACTIVITIES OF LKB1 PROTEIN KINASE AND PP2C PROTEIN
PHOSPHATASE
R. Terkeltaub1, B. Yang1, M. Lotz2, R. Liu-Bryan1. 1VAMC Med.-
Rheumatology, UCSD, San Diego, CA, USA; 2The Scripps Res. Inst., La Jolla,
CA, USA
Purpose: AMP-activated protein kinase (AMPK) is a super-regulator
of energy homeostasis and cellular metabolism, and increases muscle
stamina. In addition, AMPK suppresses inﬂammation, partly by inhibiting
NF-úB activation. Recently, reduced AMPK activity was discovered to
develop in human knee OA chondrocytes and in cultured chondrocytes
treated with the inﬂammatory cytokines IL-1b and TNFa. AMPK activators
suppress cartilage matrix degradation induced by IL-1b and TNFa in
vitro. LKB1 is the major upstream activating kinase of AMPK, and
PP2C is a protein phosphatase that can dephosphorylate AMPKa.
Here, we examined the roles of LKB1 and PP2C in regulation of
AMPK in articular chondrocytes. SIRT1, a NAD-dependent histone/protein
deacetylase, is another nutrient-sensing metabolic regulator. Decreased
SIRT1 expression is observed in human OA cartilage, and SIRT1 activity
is shown to be chondroprotective in vitro. Since SIRT1 has been
demonstrated to modulate LKB1, we also tested if SIRT1 regulates AMPK
activity in articular chondrocytes.
Methods: Expression and phosphorylation of LKB1 were examined in
human knee cartilage sections from different donors without (grade
I) and with OA (grades II-IV). We also studied normal aging mouse
knee cartilage sections (with an age range of 3, 6, 12 and 24 months).
Expression of PP2C was assessed in normal articular chondrocytes in
response to IL-1b and TNFa. LKB1 and SIRT1 were either overexpressed
or knocked down in human chondrocytes via transfection with their
cDNAs and siRNAs, respectively. Resveratrol was used to active Sirt1.
Status of acetylation of LKB1, phosphorylation of LKB1 and AMPKa were
examined, and we assayed pro-catabolic responses including nitric oxide
(NO) generation, and expression of MMP-3 in response to IL-1b and
TNFa.
Results: Decreased expression and phosphorylation of LKB1, and
concurrently AMPKa, were observed in human knee OA cartilages
compared with normal cartilage. In addition, there was age-related
loss of expression and phosphorylation of LKB1 in the aging
mouse knee cartilages. IL-1b and TNFa induced PP2Ca expression
in chondrocytes. Knockdown of LKB1 in chondrocytes resulted in
attenuated phosphorylation of AMPKa and increased NO generation (by
50% and 80%, respectively, P < 0.05) and augmented MMP-3 release in
response to IL-1b and TNFa. Activation of SIRT1 by resveratrol resulted
in de-acetylation of LKB1 and increased phosphorylation (activation
responses) of both LKB1 and AMPKa. Overexpression of SIRT1 and LKB1
increased phosphorylation of LKB1, and prevented de-phosphorylation
of AMPKa induced by IL-1b and TNFa. Last, knockdown of SIRT1 led
to decreased phosphorylation of AMPKa and increased chondrocyte
catabolic responses to IL-1b and TNFa.
Conclusions: AMPK activity is promoted by LKB1 and inhibited by PP2C
in articular chondrocytes. SIRT1 plays a central role in this functional
loop by activating AMPK, mediated by SIRT1-induced LKB1 activation in
chondrocytes. Maintenance of AMPK activity by stimulation of the LKB1
and/or inhibition of PP2C in articular chondrocytes has novel therapeutic
potential to prevent cartilage matrix degradation, and thereby to slow
progression of OA.
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OSTEOARTHRITIC ARTICULAR CARTILAGE EXPRESSES THE PTH
RECEPTOR; PTH EFFECTS CARTILAGE METABOLISM
B-C. Sondergaard1, I.J. Klausen1, N.A. Sims2, R.H. Nielsen1, J.H. Gooi2,
M.A. Karsdal1, A-C. Bay-Jensen1. 1Nordic BioSci., Herlev, Denmark; 2St.
Vincent’s Inst., Fitzroy, Australia
Purpose: The pathogenesis of osteoarthritis (OA) affects both the bone
and cartilage compartment. Parathyroid hormone (PTH) is a well-known
modulator of calcium homeostasis and exerts both anabolic and catabolic
effects on bone related to treatment of osteoporosis. PTH acts on
osteoblasts, initiating the G-coupled receptor pathway through cAMP.
Recently, cAMP has been shown to be of major importance for the
chondrocyte phenotype. We set out to investigate the effect of PTH in
relation to OA. The expression of PTH receptor 1 (PTH1R) and the effects
of PTH on human osteoarthritic cartilage were investigated in vitro. The
effect on cartilage degradation was investigated in a rodent model of
accelerated bone and cartilage loss.
Methods: In vitro: The expression of the PTH1R was investigated
in human OA chondrocytes by qPCR, the PTH1R protein by
immunohistochemistry (IHC) in full thickness cartilage explants, and
functionality by cAMP ELISA. Human OA chondrocytes were isolated by
enzyme treatment and subsequently maintained serum-free for 1 hour
in the presence of 100mM IBMX (a phosphordiesterase inhibitor), and
subsequently stimulated with PTH(1–84) 1 nM-100nM + IBMX for 30
min and the intracellular levels of cAMP were quantiﬁed by ELISA.
Direct anabolic effects of PTH were studied in vitro by stimulation of
human OA articular cartilage explants with doses of 1 nM-100 mM
PTH. The cultures were maintained for 17 days and pulsed by 5mCi
35Sulphate. Anabolic effects on proteoglycan formation were evaluated by
incorporation of 35Sulphate, followed by liquid scintillation counting in
the extracted cartilage proteoglycan. Effects on collagen type II formation
were investigated in the conditioned medium from the explants cultures
by quantiﬁcation of neo-epitopes of the N-terminal propeptide of
collagen type II by ELISA (PIINP). In vivo: Thirty 5-month old female rats
were subjected to either sham or ovariectomy (OVX), and administered
either vehicle or 30mg/kg hPTH (1–34) by s.c. injection for 5 weeks,
n = 10. Serum levels of osteocalcin and collagen type II degradation neo-
epitopes (CTX-II) were measured by ELISA.
Results: Human articular chondrocytes expressed the PTH receptor
1 as detected by qPCR and IHC. PTH stimulation induced increased
levels of intracellular cAMP (P < 0.003) compared with vehicle control.
Additionally, PTH increased the release of PIINP from OA articular
cartilage explants cultures by two-fold. Furthermore, 10nM PTH
increased incorporation of 35sulphate by 40% (P = 0.002). In the in vivo
study of rodents subjected to OVX and treated by s.c injections of PTH, the
